Beyond Biotech - the podcast from Labiotech

Beyond Biotech podcast 7: World Hepatitis Day

July 29, 2022 Labiotech
Beyond Biotech - the podcast from Labiotech
Beyond Biotech podcast 7: World Hepatitis Day
Show Notes

This week's podcast features three interviews related to hepatitis.

Our guests are Ahmed Elsharkawy, consultant transplant hepatologist and honorary senior clinical lecturer at the University of Birmingham in the UK; Ziv Ben-Ari, director of the Liver Diseases Center at the Sheba Medical Center in Israel, and James McIlroy, chief executive officer at EnteroBiotix.

World Hepatitis Day

Taking place on July 28 every year, World Hepatitis Day unites the world under a single theme to raise awareness of the global burden of viral hepatitis with the intention of influencing real change. This year’s theme is ‘I Can’t Wait’.

Dr Ahmed Elsharkawy is a consultant transplant hepatologist and honorary senior clinical lecturer at the University of Birmingham and he is also chair of hepatitis B virus special interest group which is part of the British Association for the Study of the Liver. He is a strong supporter and advocate of World Hepatitis Day. 

Professor Ziv Ben-Ari is director of the Center for Liver Diseases and Liver Research Laboratory at the Sheba Medical Center in Israel and Professor of Medicine at Tel-Aviv University.

She has more than 25 years of experience in evaluating candidates for liver transplantation and monitoring liver transplants including five years as a fellow in Hepatology and Liver Transplantation at the Royal Free Hospital, London.  She has chaired the Israeli Liver Research Society, chairs the Liver Committee of the National Council of Gastroenterology and is an active member of the American and European Association for the Study of the Liver. She has published more than 175 studies in leading medical journals.

Dr James McIlroy is a qualified medical doctor and biopharmaceutical entrepreneur widely recognized as a pioneer and thought leader in the application of the microbiome to treat disease.

He founded EnteroBiotix with the vision of building one of the world’s leading microbiome drug development companies.